Literature DB >> 35178643

Tannic Acid Attenuates Peripheral and Brain Changes in a Preclinical Rat Model of Glioblastoma by Modulating Oxidative Stress and Purinergic Signaling.

Natália Pontes Bona1, Mayara Sandrielly Pereira Soares2, Nathalia Stark Pedra2, Luiza Spohr2, Francieli da Silva Dos Santos1, Alana Seixas de Farias1, Fernando Lopez Alvez2, Bernardo de Moraes Meine1, Karina Pereira Luduvico1, Roselia Maria Spanevello2, Francieli Moro Stefanello3.   

Abstract

Glioblastoma (GB) is a highly aggressive and invasive brain tumor; its treatment remains palliative. Tannic acid (TA) is a polyphenol widely found in foods and possesses antitumor and neuroprotective activities. This study aimed to investigate the effect of TA on oxidative stress parameters and the activity of ectonucleotidases in the serum, platelets, and lymphocytes and/or in the brain of rats with preclinical GB. Rats with GB were treated intragastrically with TA (50 mg/kg/day) for 15 days or with a vehicle. In the platelets of the animals with glioma, the adenosine triphosphate (ATP) and adenosine monophosphate (AMP) hydrolysis and the catalase (CAT) activity decreased. Besides, the adenosine diphosphate (ADP) hydrolysis, adenosine (Ado) deamination, and the reactive oxygen species (ROS) and nitrite levels were increased in glioma animals; however, TA reversed ROS and nitrite levels and AMP hydrolysis alterations. In lymphocytes from animals with glioma, the ATP and ADP hydrolysis, as well as Ado deamination were increased; TA treatment countered this increase. In the brain of the animals with glioma, the ROS, nitrite, and thiobarbituric acid reactive substance (TBARS) levels increased and the thiol (SH) levels and CAT and superoxide dismutase (SOD) activities were decreased; TA treatment decreased the ROS and TBARS levels and restored the SOD activity. In the serum of the animals with glioma, the ATP hydrolysis decreased; TA treatment restored this parameter. Additionally, the ROS levels increased and the SH and SOD activity decreased by glioma implant; TA treatment enhanced nitrite levels and reversed SOD activity. Altogether, our results suggest that TA is an important target in the treatment of GB, as it modulates purinergic and redox systems.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer; Ectoenzymes; Glioma; Polyphenols; Redox status; Tannin

Mesh:

Substances:

Year:  2022        PMID: 35178643     DOI: 10.1007/s11064-022-03547-7

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  40 in total

1.  International conference on purinergic drugs and targets-4th joint german-italian purine club meeting, bonn, Germany, july 22-25, 2011.

Authors:  Renata Ciccarelli; Christa E Müller; Herbert Zimmermann
Journal:  Purinergic Signal       Date:  2012-03       Impact factor: 3.765

Review 2.  Management of glioblastoma: State of the art and future directions.

Authors:  Aaron C Tan; David M Ashley; Giselle Y López; Michael Malinzak; Henry S Friedman; Mustafa Khasraw
Journal:  CA Cancer J Clin       Date:  2020-06-01       Impact factor: 508.702

3.  Spinal Drop Metastasis of Glioblastoma-Two Case Reports, Clinicopathologic Features, Current Modalities of Evaluation, and Treatment with a Review of the Literature.

Authors:  Anil Pande; Nikitha Rajaraman; Naimathullah Sadiya; Sushama Patil; Senguttuvan Pandian; Rajendran Adhithyan; Babu Rajendran; Rakesh Jalali; Siddhartha Ghosh
Journal:  World Neurosurg       Date:  2020-11-05       Impact factor: 2.104

4.  Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.

Authors:  Hanmei Li; Sonja Krstin; Michael Wink
Journal:  Phytomedicine       Date:  2018-09-17       Impact factor: 5.340

5.  CD73 Downregulation Decreases In Vitro and In Vivo Glioblastoma Growth.

Authors:  J H Azambuja; N E Gelsleichter; L R Beckenkamp; I C Iser; M C Fernandes; F Figueiró; A M O Battastini; J N Scholl; F H de Oliveira; R M Spanevello; Jean Sévigny; M R Wink; M A Stefani; H F Teixeira; Elizandra Braganhol
Journal:  Mol Neurobiol       Date:  2018-08-16       Impact factor: 5.590

6.  Glioblastoma multiforme: novel therapeutic targets.

Authors:  Matthew Muir; Sricharan Gopakumar; Jeffrey Traylor; Sungho Lee; Ganesh Rao
Journal:  Expert Opin Ther Targets       Date:  2020-05-12       Impact factor: 6.902

Review 7.  Potential implications of hydrogen peroxide in the pathogenesis and therapeutic strategies of gliomas.

Authors:  Ying Zhou; Long Wang; Chaojia Wang; Yilin Wu; Dongmei Chen; Tae Ho Lee
Journal:  Arch Pharm Res       Date:  2020-01-19       Impact factor: 4.946

Review 8.  Extracellular purines, purinergic receptors and tumor growth.

Authors:  F Di Virgilio; E Adinolfi
Journal:  Oncogene       Date:  2016-06-20       Impact factor: 9.867

Review 9.  Drug Resistance in Glioblastoma: The Two Faces of Oxidative Stress.

Authors:  Christophe Olivier; Lisa Oliver; Lisenn Lalier; François M Vallette
Journal:  Front Mol Biosci       Date:  2021-01-27

Review 10.  Natural products and their derivatives: Promising modulators of tumor immunotherapy.

Authors:  Li-Juan Deng; Ming Qi; Nan Li; Yu-He Lei; Dong-Mei Zhang; Jia-Xu Chen
Journal:  J Leukoc Biol       Date:  2020-07-17       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.